Drug Combination Details
| General Information of the Combination (ID: C99555) | |||||
|---|---|---|---|---|---|
| Name | Wogonoside NP Info | + | Dextran sulfate sodium Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colitis
[ICD-11: 1A40]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | NLRP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NOS2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | ||
| In-vivo Model | Acute colitis was induced by administration of DSS in drinking water in 35-40 days old female BALB/c mice, weighing 18-22 g, | |||||
| Experimental
Result(s) |
Wogonoside may exert its anti-inflammatory effect via dual inhibition of NF-KappaB and NLRP3 inflammasome, suggesting that wogonoside might be a potential effective drug for inflammatory bowel diseases. | |||||
